at MarketWatch.com (Jun 25, 2012)
Analyst Sharon di Stefano calls two upcoming trials of Medgenics' (MDGN -3%) Infraddure Biopump for treating hepatitis C as "a leap forward for viral medicine no less important than the first studies in HIV decades ago." And with the recent failure of a Bristol-Myers treatment in clinical trials, the timing is good. Still, with a number of rival drugs being trialled, one wonders whether di Stefano is guilty of hyperbole.
From other sites